Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Polymyositis Market Size Changed, over the years?

The market size for polymyositis has seen robust growth in the past couple of years. There is an expectation of its growth from $1.65 billion in 2024 to about $1.75 billion by 2025, showing a compound annual growth rate (CAGR) of 6.4%. This upward trajectory in the past period is due to improved access to developing regions, heightened usage of prednisone, increased appeal of methotrexate for symptom management, a surge in application of TNF inhibitors, and a rise in the use of antibody testing.

How Much Will the Polymyositis Market Be Worth in 2029?

The market size for polymyositis is projected to experience robust growth in the next several years, reaching $2.23 billion in 2029 with a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during the forecast period is linked to an increase in telemedicine, utilization of remote monitoring, a rising trend in the use of immuno-suppressants, growth in stem cell therapy, and expansion of biosimilars usage. Key trends projected during this time include the incorporation of artificial intelligence within drug discovery, advancements in targeted therapies, the establishment of innovative immunomodulators, an increase in regenerative medicine research, and the assimilation of big data.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

Which is the Largest Company in the Polymyositis Market?

Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited

What Are the Main Market Drivers in the Polymyositis Industry?

The surge in autoimmune diseases is projected to boost the polymyositis market’s expansion. Autoimmune diseases consist of medical ailments where the body’s immune system erroneously assaults its own healthy cells, tissues, or organs, resulting in inflammation and harm. Autoimmune disorders are escalating as specific genetic variations can facilitate an excessive immune response, making individuals more prone to inadvertently attack their own tissues. This genetic predisposition, together with environmental triggers like infections, stress, and lifestyle factors, contributes to the growing occurrence of autoimmune disorders. Polymyositis aids in elucidating autoimmune ailments by showing how immune system malfunction leads to muscle inflammation, providing information into the foundational mechanisms and potential cures for related disorders. For instance, Versorgungsatlas.de, a German organization, reported in November 2024 that out of 73,241,305 insured persons in 2022, 6,304,340 were diagnosed with at least one autoimmune disease. This translates to an unadjusted prevalence rate of 8.61%. Hence, the swell in autoimmune diseases is propelling the Polymyositis market. Additionally, the escalating demand for oral drugs is anticipated to drive the polymyositis market’s growth. Oral drugs, including tablets, capsules, or liquids, are absorbed via the digestive system and are convenient, easy to administer. They offer patients a non-invasive treatment option, which makes them preferable over injections or other delivery methods. Oral drugs used to treat polymyositis work to diminish muscle inflammation, regulate the immune system, and improve muscle functionality, thus easing symptoms and slowing disease progression. According to a report by the US-based Centers for Disease Control and Prevention in October 2022, the dispensing of oral antivirals increased by 57%, rising from 643 per 100,000 individuals between April 24 and May 21, 2022, to 1,012 per 100,000 individuals from July 31 to August 28, 2022. Hence, the increased demand for oral drugs is fueling the expansion of the polymyositis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp

How Is the Polymyositis Market Segments Structured?

The polymyositis market covered in this report is segmented –

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes

2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)

3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies

4) By Distribution Channel: Offline, Online

5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegmentss:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis

2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis

3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy

4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

What Strategic Trends Are Transforming the Polymyositis Market?

Significant players in the polymyositis market are concentrating on the creation of novel treatments like stem cell therapy to improve therapy effectiveness and decelerate disease progression. Stem cell therapy employs umbilical cord-derived stem cells for regenerative treatment. These cells possess potent anti-inflammatory and immunomodulatory characteristics, positioning them as a potent alternative for the treatment of autoimmune disorders such as polymyositis. For example, RESTEM, a clinical-stage biotech firm based in the U.S, earned Orphan Drug Designation (ODD) in December 2024 from the U.S Food and Drug Administration (FDA) for their stem cell program that utilizes umbilical cord outer lining stem cells (ULSCs). This program uses these stem cells in the treatment of polymyositis and Dermatomyositis by managing the immune system and lessening muscle inflammation. This therapy has demonstrated hopeful safety and effectiveness in preliminary tests, with the possibility to reduce steroid dependency.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

Which Global Regions Offer the Highest Growth in the Polymyositis Market?

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22104

This Report Delivers Insight On:

1. How big is the polymyositis market, and how is it changing globally?

2. Who are the major companies in the polymyositis market, and how are they performing?

3. What are the key opportunities and risks in the polymyositis market right now?

4. Which products or customer segments are growing the most in the polymyositis market?

5. What factors are helping or slowing down the growth of the polymyositis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model